"Compliance of the Indian National Task Force guidelines for COVID-19 recommendation by Indian doctors - A survey".
Identifieur interne : 000F75 ( Main/Corpus ); précédent : 000F74; suivant : 000F76"Compliance of the Indian National Task Force guidelines for COVID-19 recommendation by Indian doctors - A survey".
Auteurs : Kalyan Kumar Gangopadhyay ; Binayak Sinha ; Samit GhosalSource :
- Diabetes & metabolic syndrome [ 1878-0334 ]
English descriptors
- KwdEn :
- Adult (MeSH), COVID-19 (MeSH), Coronavirus Infections (diagnosis), Coronavirus Infections (drug therapy), Coronavirus Infections (prevention & control), Female (MeSH), Guideline Adherence (statistics & numerical data), Humans (MeSH), India (MeSH), Male (MeSH), Middle Aged (MeSH), Pandemics (prevention & control), Physicians (statistics & numerical data), Pneumonia, Viral (diagnosis), Pneumonia, Viral (drug therapy), Pneumonia, Viral (prevention & control), Surveys and Questionnaires (MeSH).
- MESH :
- geographic : India.
- diagnosis : Coronavirus Infections, Pneumonia, Viral.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- prevention & control : Coronavirus Infections, Pandemics, Pneumonia, Viral.
- statistics & numerical data : Guideline Adherence, Physicians.
- Adult, COVID-19, Female, Humans, Male, Middle Aged, Surveys and Questionnaires.
Abstract
BACKGROUND AND AIMS
As the Coronavirus disease 2019 (COVID-19) pandemic unravels rapidly, there is a glut of confusing and divergent scientific information emanating from differing sources, including the Indian National Task Force for COVID-19. Thus, a web-based survey was conducted to decipher the approach of Indian doctors to the various options for treatment of COVID-19.
METHODS
A web-based questionnaire among one lakh doctors across India through email and social media was circulated. After data quality and internal validation, 826 responses were included for analysis. Basic demographic and comparative analysis were performed using the Python3.8.2 software (Windows 10 64 bit, USA).
RESULTS
Amongst all the states of India most respondents hailed from the top ten affected states. Overall 76.15% of doctors would either prescribe or consider prescribing hydroxychloroquine (HCQ) as prophylaxis for health-care providers (HCP). Doctors with experience of managing COVID-19 were more likely to advocate use of HCQ as prophylaxis for HCP (χ2 = 4.357, P = 0.037). Intensivists were more likely to advocate HCQ as prophylaxis (χ2 = 14.588, P < 0.001) as well as for management of mild to moderate COVID-19 (χ2 = 3.91, P = 0.048). In COVID-19, 65.8% doctors overwhelmingly preferred using anti-viral agents in severe cases, continuing ACEi/ARB (60.9%), and routinely screening for COVID-19 as a pre-operative strategy (73.85%).
CONCLUSIONS
Indian doctors are largely following the scientific guidance provided by Indian National Task Force for COVID-19 and would consider prescribing HCQ as prophylaxis for COVID-19. They would also consider using it in mild to moderate COVID-19.
DOI: 10.1016/j.dsx.2020.07.040
PubMed: 32755844
PubMed Central: PMC7381897
Links to Exploration step
pubmed:32755844Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">"Compliance of the Indian National Task Force guidelines for COVID-19 recommendation by Indian doctors - A survey".</title><author><name sortKey="Gangopadhyay, Kalyan Kumar" sort="Gangopadhyay, Kalyan Kumar" uniqKey="Gangopadhyay K" first="Kalyan Kumar" last="Gangopadhyay">Kalyan Kumar Gangopadhyay</name><affiliation><nlm:affiliation>Department of Diabetes & Endocrinology, Fortis Hospital, Peerless Hospital, 730, Eastern Metropolitan Bypass, Kolkata, India. Electronic address: jaykal69@hotmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Sinha, Binayak" sort="Sinha, Binayak" uniqKey="Sinha B" first="Binayak" last="Sinha">Binayak Sinha</name><affiliation><nlm:affiliation>Department of Diabetes & Endocrinology, Fortis Hospital, AMRI Hospital, 730, Eastern Metropolitan Bypass, 700107, Kolkata, India. Electronic address: binayak.sinha@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Ghosal, Samit" sort="Ghosal, Samit" uniqKey="Ghosal S" first="Samit" last="Ghosal">Samit Ghosal</name><affiliation><nlm:affiliation>Department of Diabetes & Endocrinology, Nightingale Hospital, 11, Shakespeare Sarani, Midleton Row, Kolkata, 700071, India. Electronic address: ramdasghosal@gmail.com.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020 Sep - Oct</date><idno type="RBID">pubmed:32755844</idno><idno type="pmid">32755844</idno><idno type="doi">10.1016/j.dsx.2020.07.040</idno><idno type="pmc">PMC7381897</idno><idno type="wicri:Area/Main/Corpus">000F75</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000F75</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">"Compliance of the Indian National Task Force guidelines for COVID-19 recommendation by Indian doctors - A survey".</title><author><name sortKey="Gangopadhyay, Kalyan Kumar" sort="Gangopadhyay, Kalyan Kumar" uniqKey="Gangopadhyay K" first="Kalyan Kumar" last="Gangopadhyay">Kalyan Kumar Gangopadhyay</name><affiliation><nlm:affiliation>Department of Diabetes & Endocrinology, Fortis Hospital, Peerless Hospital, 730, Eastern Metropolitan Bypass, Kolkata, India. Electronic address: jaykal69@hotmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Sinha, Binayak" sort="Sinha, Binayak" uniqKey="Sinha B" first="Binayak" last="Sinha">Binayak Sinha</name><affiliation><nlm:affiliation>Department of Diabetes & Endocrinology, Fortis Hospital, AMRI Hospital, 730, Eastern Metropolitan Bypass, 700107, Kolkata, India. Electronic address: binayak.sinha@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Ghosal, Samit" sort="Ghosal, Samit" uniqKey="Ghosal S" first="Samit" last="Ghosal">Samit Ghosal</name><affiliation><nlm:affiliation>Department of Diabetes & Endocrinology, Nightingale Hospital, 11, Shakespeare Sarani, Midleton Row, Kolkata, 700071, India. Electronic address: ramdasghosal@gmail.com.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Diabetes & metabolic syndrome</title><idno type="eISSN">1878-0334</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (diagnosis)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (prevention & control)</term><term>Female (MeSH)</term><term>Guideline Adherence (statistics & numerical data)</term><term>Humans (MeSH)</term><term>India (MeSH)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Pandemics (prevention & control)</term><term>Physicians (statistics & numerical data)</term><term>Pneumonia, Viral (diagnosis)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (prevention & control)</term><term>Surveys and Questionnaires (MeSH)</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>India</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term><term>Pandemics</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Guideline Adherence</term><term>Physicians</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>COVID-19</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Surveys and Questionnaires</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND AND AIMS</b></p><p>As the Coronavirus disease 2019 (COVID-19) pandemic unravels rapidly, there is a glut of confusing and divergent scientific information emanating from differing sources, including the Indian National Task Force for COVID-19. Thus, a web-based survey was conducted to decipher the approach of Indian doctors to the various options for treatment of COVID-19.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>A web-based questionnaire among one lakh doctors across India through email and social media was circulated. After data quality and internal validation, 826 responses were included for analysis. Basic demographic and comparative analysis were performed using the Python3.8.2 software (Windows 10 64 bit, USA).</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Amongst all the states of India most respondents hailed from the top ten affected states. Overall 76.15% of doctors would either prescribe or consider prescribing hydroxychloroquine (HCQ) as prophylaxis for health-care providers (HCP). Doctors with experience of managing COVID-19 were more likely to advocate use of HCQ as prophylaxis for HCP (χ2 = 4.357, P = 0.037). Intensivists were more likely to advocate HCQ as prophylaxis (χ2 = 14.588, P < 0.001) as well as for management of mild to moderate COVID-19 (χ2 = 3.91, P = 0.048). In COVID-19, 65.8% doctors overwhelmingly preferred using anti-viral agents in severe cases, continuing ACEi/ARB (60.9%), and routinely screening for COVID-19 as a pre-operative strategy (73.85%).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Indian doctors are largely following the scientific guidance provided by Indian National Task Force for COVID-19 and would consider prescribing HCQ as prophylaxis for COVID-19. They would also consider using it in mild to moderate COVID-19.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32755844</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-0334</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>5</Issue><PubDate><MedlineDate>2020 Sep - Oct</MedlineDate></PubDate></JournalIssue><Title>Diabetes & metabolic syndrome</Title><ISOAbbreviation>Diabetes Metab Syndr</ISOAbbreviation></Journal><ArticleTitle>"Compliance of the Indian National Task Force guidelines for COVID-19 recommendation by Indian doctors - A survey".</ArticleTitle><Pagination><MedlinePgn>1413-1418</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1871-4021(20)30289-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.dsx.2020.07.040</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">As the Coronavirus disease 2019 (COVID-19) pandemic unravels rapidly, there is a glut of confusing and divergent scientific information emanating from differing sources, including the Indian National Task Force for COVID-19. Thus, a web-based survey was conducted to decipher the approach of Indian doctors to the various options for treatment of COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A web-based questionnaire among one lakh doctors across India through email and social media was circulated. After data quality and internal validation, 826 responses were included for analysis. Basic demographic and comparative analysis were performed using the Python3.8.2 software (Windows 10 64 bit, USA).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Amongst all the states of India most respondents hailed from the top ten affected states. Overall 76.15% of doctors would either prescribe or consider prescribing hydroxychloroquine (HCQ) as prophylaxis for health-care providers (HCP). Doctors with experience of managing COVID-19 were more likely to advocate use of HCQ as prophylaxis for HCP (χ2 = 4.357, P = 0.037). Intensivists were more likely to advocate HCQ as prophylaxis (χ2 = 14.588, P < 0.001) as well as for management of mild to moderate COVID-19 (χ2 = 3.91, P = 0.048). In COVID-19, 65.8% doctors overwhelmingly preferred using anti-viral agents in severe cases, continuing ACEi/ARB (60.9%), and routinely screening for COVID-19 as a pre-operative strategy (73.85%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Indian doctors are largely following the scientific guidance provided by Indian National Task Force for COVID-19 and would consider prescribing HCQ as prophylaxis for COVID-19. They would also consider using it in mild to moderate COVID-19.</AbstractText><CopyrightInformation>Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gangopadhyay</LastName><ForeName>Kalyan Kumar</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Department of Diabetes & Endocrinology, Fortis Hospital, Peerless Hospital, 730, Eastern Metropolitan Bypass, Kolkata, India. Electronic address: jaykal69@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinha</LastName><ForeName>Binayak</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Diabetes & Endocrinology, Fortis Hospital, AMRI Hospital, 730, Eastern Metropolitan Bypass, 700107, Kolkata, India. Electronic address: binayak.sinha@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosal</LastName><ForeName>Samit</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Diabetes & Endocrinology, Nightingale Hospital, 11, Shakespeare Sarani, Midleton Row, Kolkata, 700071, India. Electronic address: ramdasghosal@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Diabetes Metab Syndr</MedlineTA><NlmUniqueID>101462250</NlmUniqueID><ISSNLinking>1871-4021</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019983" MajorTopicYN="N">Guideline Adherence</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010820" MajorTopicYN="N">Physicians</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Doctors</Keyword><Keyword MajorTopicYN="N">HCQ</Keyword><Keyword MajorTopicYN="N">Physicians</Keyword><Keyword MajorTopicYN="N">Prophylaxis</Keyword><Keyword MajorTopicYN="N">Survey</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors do not have any conflict of interest to declare for this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>07</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>07</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32755844</ArticleId><ArticleId IdType="pii">S1871-4021(20)30289-7</ArticleId><ArticleId IdType="doi">10.1016/j.dsx.2020.07.040</ArticleId><ArticleId IdType="pmc">PMC7381897</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>BMJ. 2020 May 14;369:m1849</Citation><ArticleIdList><ArticleId IdType="pubmed">32409561</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2020 Aug 18;173(4):287-296</Citation><ArticleIdList><ArticleId IdType="pubmed">32459529</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Aug 6;383(6):517-525</Citation><ArticleIdList><ArticleId IdType="pubmed">32492293</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Nov 5;383(19):1827-1837</Citation><ArticleIdList><ArticleId IdType="pubmed">32459919</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 May 22;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32450107</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2020 May;94:91-95</Citation><ArticleIdList><ArticleId IdType="pubmed">32173574</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Aug 6;383(6):585-586</Citation><ArticleIdList><ArticleId IdType="pubmed">32492298</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Metab Syndr. 2020 Jul - Aug;14(4):641-648</Citation><ArticleIdList><ArticleId IdType="pubmed">32428865</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jun;55(6):105988</Citation><ArticleIdList><ArticleId IdType="pubmed">32305587</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pharmacol Rep. 2020 May 11;:1-15</Citation><ArticleIdList><ArticleId IdType="pubmed">32395418</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Respir Cell Mol Biol. 2020 Jul;63(1):132-133</Citation><ArticleIdList><ArticleId IdType="pubmed">32315548</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 Sep;92(9):1475-1483</Citation><ArticleIdList><ArticleId IdType="pubmed">32356910</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2020 Oct;20(10):1118-1119</Citation><ArticleIdList><ArticleId IdType="pubmed">32311324</ArticleId></ArticleIdList></Reference><Reference><Citation>Indian J Med Res. 2020 May;151(5):459-467</Citation><ArticleIdList><ArticleId IdType="pubmed">32611916</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation><ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Metab Syndr. 2020 Jul - Aug;14(4):589-596</Citation><ArticleIdList><ArticleId IdType="pubmed">32417708</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Nov 5;71(8):1953-1959</Citation><ArticleIdList><ArticleId IdType="pubmed">32382743</ArticleId></ArticleIdList></Reference><Reference><Citation>BJGP Open. 2020 Jun 23;4(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">32398343</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2020 Mar 06;69(9):245-246</Citation><ArticleIdList><ArticleId IdType="pubmed">32134909</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F75 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000F75 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32755844
|texte= "Compliance of the Indian National Task Force guidelines for COVID-19 recommendation by Indian doctors - A survey".
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32755844" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |